Trial reportBMC endocrine disorders2022
Associations between serum vitamin D
Trial report in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Pooled it
- Relationship between Vitamin D Insufficiency, Lipid Profile and Atherogenic Indices in Healthy Women Aged 18-50 Years.European journal of investigation in health, psychology and education · 2024Article
- Atherogenic Index of Plasma (AIP) and Its Association with Fatty Liver in Obese Adolescents.Children (Basel, Switzerland) · 2023Article
- Vitamin D insufficiency and its association with adipokines and atherogenic indices in patients with metabolic syndrome: A case-control study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought the association between serum 25-hydroxyvitamin D
methodsThe present study was a nested case-control study conducted on 252 participants with T2DM and controls from the second phase of the KERCADR cohort study. The participants with a mean (±SD) age of 49.79 ± 5.85 years were randomly selected and allocated into case and control groups. Independent t-test, Hierarchical Linear Regression, Univariate ANOVA, and partial correlation were used for analysis the data. Atherogenic indices of plasma include Castelli Risk Index I (CRI I), Castelli Risk Index II (CRI II), and the novel Atherogenic Index of Plasma (AIP), and Atherogenic Coefficient (AC).
resultsThere was a significant difference among case and control groups for AIP in males and females (P < 0.001 and P = 0.007, respectively). The levels of AIP, CRI I, and AC significantly decreased (P = 0.017, P = 0.029, and P = 0.029, respectively) with improved serum vitamin D status only in control male participants. The main effect of BMI and vitamin D status on AIP, CRI I, and AC, and the main effect of BMI on CRI I, CRI II, and AC were significant in control males and females, respectively.
conclusionWe conclude that there is a reverse significant association between AIP and serum vitamin D among healthy males. Low serum level of vitamin D is associated with atherogenic dyslipidemia. Therefore, improving vitamin D status as an important indicator may alleviate AIP as a surrogate marker for predicting the risk of CVD events in healthy men and women with normal BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.